Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Denosumab is a prescription monoclonal antibody that blocks RANK ligand. Different denosumab products have different indications and doses. Prolia is used for selected osteoporosis and treatment-related bone loss conditions, while Xgeva is used for cancer-related bone complications, giant cell tumor of bone, and hypercalcemia of malignancy refractory to bisphosphonate therapy.
read more about denosumab ...Denosumab binds RANK ligand and prevents it from activating the RANK receptor on osteoclasts and their precursors. This reduces osteoclast formation, function, and survival. Reduced osteoclast activity lowers bone resorption and changes calcium release from bone.
Prolia treats osteoporosis in postmenopausal women and men at high fracture risk, glucocorticoid-induced osteoporosis, and selected bone loss during prostate or breast cancer therapy. Xgeva prevents skeletal-related events in multiple myeloma or solid-tumor bone metastases and treats selected giant cell tumor of bone and refractory hypercalcemia of malignancy.
Prolia is given as 60 mg subcutaneously once every six months, with calcium and vitamin D supplementation. Xgeva commonly uses 120 mg subcutaneously every four weeks. Giant cell tumor of bone and hypercalcemia of malignancy also use extra 120 mg doses on days 8 and 15 of the first month.
Prolia carries a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease. Other serious concerns across denosumab products include hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, serious infections, hypersensitivity, and fetal harm. Stopping Prolia without another osteoporosis treatment can increase the risk of multiple vertebral fractures.
Yes. Denosumab binds RANK ligand and reduces osteoclast formation, function, and survival.
Prolia is administered as a 60 mg subcutaneous injection once every six months.
Xgeva is administered as 120 mg subcutaneously every four weeks for bone metastases and multiple myeloma.
Yes. Severe hypocalcemia can occur, with greater risk in advanced chronic kidney disease.
DailyMed - PROLIA (denosumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88. Date Accessed September 24, 2026.
DailyMed - XGEVA (denosumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=628f0998-1206-4001-aeee-18133aa9f3bf. Date Accessed September 24, 2026.
Denosumab. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/denosumab. Date Accessed September 24, 2026.
Denosumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a610023.html. Date Accessed September 24, 2026.
PROLIA (denosumab) Prescribing Information. Amgen. https://www.pi.amgen.com/united_states/prolia/prolia_pi.pdf. Date Accessed September 24, 2026.